Hosted on MSN1d
Morgan Stanley Upgrades Quest Diagnostics (DGX)
Fintel reports that on December 17, 2024, Morgan Stanley upgraded their outlook for Quest Diagnostics (NYSE:DGX) from ...
Business Insider5d
Quest Diagnostics price target raised to $182 from $179 at BofA
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $179 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...